Israel - hebreu - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin; pertussis toxoid (pt); tetanus toxoid - תרחיף להזרקה - diphtheria toxoid nlt 30 iu; tetanus toxoid nlt 40 iu; pertactin 8 mcg / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml - bacterial and viral vaccines, combined - infanrix is indicated as a booster dose for children 15 months to 7 years of age who have previously been immunised with three or four doses of either dtpa vaccine or diphtheria, tetanus and whole-cell pertussis (dtpw) vaccine. active primary immunisation against diphteria, tetanus and pertussis from the age 2 months onward.

Israel - hebreu - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

Israel - hebreu - Ministry of Health

padagis israel agencies ltd, israel - propranolol as hydrochloride - תמיסה - propranolol as hydrochloride 3.75 mg / 1 ml - propranolol

Israel - hebreu - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Israel - hebreu - Ministry of Health

אלקליל בעמ - הזנה לפנים

Israel - hebreu - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Israel - hebreu - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Israel - hebreu - Ministry of Health

teva israel ltd - hydrocortisone; neomycin as sulfate - משחה - neomycin as sulfate 0.5 %; hydrocortisone 2.5 % - hydrocortisone and antibiotics - hydrocortisone and antibiotics - allergic dermatoses and other corticosteroid responsive inflammatory skin diseases including atopic dermatitis, contact dermatitis, seborrheic dermatitis, anogenital pruritus, infantile eczema and external otitis.

Israel - hebreu - Ministry of Health

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Israel - hebreu - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.